Immunocore Confirms NASDAQ Listing of ADSs in 8-K Filing

Ticker: IMCR · Form: 8-K · Filed: Jan 5, 2024 · CIK: 1671927

Immunocore Holdings PLC 8-K Filing Summary
FieldDetail
CompanyImmunocore Holdings PLC (IMCR)
Form Type8-K
Filed DateJan 5, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$450 million
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, listing-status, compliance

TL;DR

**Immunocore's ADSs are still trading on NASDAQ, confirmed by a routine 8-K.**

AI Summary

Immunocore Holdings plc filed an 8-K on January 5, 2024, to announce that its American Depositary Shares, each representing one ordinary share with a nominal value of £0.002, are registered on NASDAQ. This filing is a routine update, indicating the company's compliance with SEC regulations and confirming its listing status. For investors, this means Immunocore's shares continue to be publicly traded and accessible on a major exchange, which is important for liquidity and transparency.

Why It Matters

This filing confirms Immunocore's continued compliance with listing requirements and provides transparency for investors regarding its publicly traded securities.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not indicate any new financial or operational risks for Immunocore Holdings plc.

Analyst Insight

A smart investor would note this as a routine compliance filing, confirming the company's continued public trading status, but it offers no new material information for investment decisions.

Key Numbers

  • £0.002 — Nominal value per ordinary share (This is the stated value of each underlying ordinary share represented by an American Depositary Share.)

Key Players & Entities

  • Immunocore Holdings plc (company) — the registrant filing the 8-K
  • NASDAQ (company) — the exchange where Immunocore's ADSs are registered
  • £0.002 (dollar_amount) — nominal value of each ordinary share

FAQ

What is the purpose of Immunocore Holdings plc's 8-K filing dated January 5, 2024?

The 8-K filing by Immunocore Holdings plc on January 5, 2024, serves to report on 'Results of Operations and Financial Condition,' 'Regulation FD Disclosure,' 'Other Events,' and 'Financial Statements and Exhibits,' and specifically confirms the registration of its American Depositary Shares on NASDAQ.

On which exchange are Immunocore Holdings plc's American Depositary Shares registered?

Immunocore Holdings plc's American Depositary Shares are registered on NASDAQ, as stated in the filing under 'Name of each exchange on which registered'.

What is the nominal value of each ordinary share represented by Immunocore's American Depositary Shares?

Each American Depositary Share represents one ordinary share with a nominal value of £0.002, according to the 'Title of each class' section of the filing.

What is the Commission File Number for Immunocore Holdings plc?

The Commission File Number for Immunocore Holdings plc is 001-39992, as indicated in the filing.

What is the business address of Immunocore Holdings plc as listed in the filing?

The business address of Immunocore Holdings plc is 92 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom OX14 4RY, as specified in the 'Address of principal executive offices' section.

Filing Stats: 924 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2024-01-05 07:19:06

Key Financial Figures

  • $450 million — of December 31, 2023 were approximately $450 million. The information in this Item 2.02 is

Filing Documents

02

Item 2.02. Results of Operations and Financial Condition. On January 5, 2024, Immunocore Holdings plc (the "Company") announced a preliminary estimate of the amount of its cash and cash equivalents at December 31, 2023. The Company preliminarily estimates that its cash and cash equivalents as of December 31, 2023 were approximately $450 million. The information in this Item 2.02 is preliminary, has not been audited and is subject to change pending completion of the Company's audited financial statements for the year ended December 31, 2023. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amounts included in this Item 2.02, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2023.

01

Item 7.01. Regulation FD Disclosure. On January 5, 2024, the Company issued a press release announcing its strategic priorities and planned pipeline expansion for 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Also on January 5, 2024, the Company updated its corporate presentation to reflect certain business and strategic updates. The Company intends to use this presentation in meetings with analysts, investors and others from time to time, including its presentation by management at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 9:00 a.m. PT. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. The corporate presentation and a webcast of the Company's presentation at the 42nd Annual J.P. Morgan Healthcare Conference will also be available in the "Investors/Media" section of the Company's website at www.immunocore.com. The Company's website and any information contained on the Company's website are not incorporated by reference into this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01

Item 8.01 Other Events. On January 5, 2024, the Company published an updated pipeline chart of KIMMRAK and its therapeutic candidates in development, which is filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated by reference herein.

Financial Statements and Exhibits

Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated January 5, 2024. 99.2 January 2024 Corporate Presentation. 99.3 Pipeline Chart.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: January 5, 2024 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.